Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $203,809 — The overall goals of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in DH270 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice with V3- Man9 glycopeptide primes and modified mRNA boosts (Project 1, Aim 2), by performing immunization studie…
Sallie R. Permar · DUKE UNIVERSITY · 2020 · $244,720 — ABSTRACT – Project 1 There is a critical need to protect adolescents and young adults from HIV infection through the development of an early life vaccine strategy that elicits protective immunity prior to sexual debut. However, to date, efforts to develop a vaccine that can elicit protective broadly…
STANLEY FIELDS · UNIVERSITY OF WASHINGTON · 2020 · $312,822 — Project Summary In TR&D 1, we develop approaches to make complex changes to cells, and we generate biosensors to report on the effects of some of these changes. In the first aim, we establish strategies to rapidly and combinatorially up- or down-regulate a set of genes in a common pathway in order t…
Genevieve Giny Fouda Amou ou · DUKE UNIVERSITY · 2020 · $546,751 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
Joanna Phillips · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $180,622 — PROJECT SUMMARY The UCSF Brain Tumor SPORE Biospecimen/Pathology Core provides staff and technology dedicated to the procurement, processing, storing, distribution, and histopathologic analysis of high-quality brain tumor biospecimens for translational science research. Our mission is to enhance bio…
Karen N. Allen · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $453,520 — Complex glycoconjugates play a pivotal role in bacterial survival, colonization, and virulence, and contribute to the interactions between symbiotic and pathogenic bacteria and their human hosts. Assembly of these macromolecules is initiated on the cytoplasmic face of cell membranes, catalyzed by po…
Briana Shimada · UNIVERSITY OF HAWAII AT MANOA · 2024 · $155,398 — This proposal will investigate the role of the selenium (Se)-recycling enzyme, selenocysteine lyase (Scly), in combination with high fructose and dietary Se deficiency impacts cardiac function. Se deficiency has been associated with an increased risk of cardiometabolic disorders including type 2 …
GABOR J TIGYI · UNIVERSITY OF MARYLAND BALTIMORE · 2024 · $286,130 — The US population at large, and particularly military personnel and first responders, are at risk of radiation expo-sure due to the explosion of a nuclear device, a nuclear reactor accident, and the threat of radiation terrorism. There is no radiation medical countermeasure (RCM) drug approved by t…
Huan Xie · TEXAS SOUTHERN UNIVERSITY · 2024 · $342,330 — PROJECT SUMMARY Prostate cancer (PCa) is the second leading cause of cancer death in the United States among men and it is more common in African American males. Despite initial good responses to androgen deprivation or anti- androgen drugs, tumors invariably recur and develop into lethal castration…
Irina A. Kirpich · UNIVERSITY OF LOUISVILLE · 2024 · $245,405 — Alcoholic liver disease (ALD) is a major and increasing health problem in the US (especially in Kentucky) and worldwide. In spite of the magnitude of this problem, there is no FDA-approved therapy for any stage of ALD. In addition, the mechanisms and regulators of the disease progression and severit…
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2024 · $410,686 — Project Abstract Merkel cell carcinoma (MCC) is one of the most aggressive skin cancers. Clonal integration of Merkel cell polyomavirus (MCPyV) genome into the host DNA has been observed in ~80% of MCCs, and represents a key causal factor for MCC development. LT and sT encoded by MCPyV genome have b…
Sheng Tong · UNIVERSITY OF KENTUCKY · 2024 · $191,250 — Summary CRISPR/cas9 gene editing has shown great promise for the treatment of genetic hematologic disorders including sickle cell disease and β-thalassemia. Current therapeutic strategies are primarily focused on ex vivo gene editing of autologous patient-derived hematopoietic stem/progenitor cells …
Maegan M Weltzin · UNIVERSITY OF ALASKA FAIRBANKS · 2024 · $77,500 — ABSTRACT. In the U.S., major depressive disorder (MDD) is the most common mental disorder, with depression prevalence approaching 20% among adolescents and young adults. Current pharmacological treatments are unsatisfactory in that 33-55% of people suffering from MDD are non-responsive. MDD is assoc…
THOMAS D. SCHMITTGEN · UNIVERSITY OF FLORIDA · 2024 · $203,188 — Project Summary Pancreatic ductal adenocarcinoma (PDAC) is currently the third most lethal cancer in the United States. It is currently the third leading of cancer-related deaths in the United States and by the end of this decade, pancreatic cancer is predicted to pass colorectal cancer, making it t…
Qingxin Mu · UNIVERSITY OF WASHINGTON · 2024 · $168,413 — Project Description Triple negative breast cancer (TNBC) is the most challenging subtype to treat among all breast cancer cases due to lack of cell surface receptors. Patients with metastatic TNBC have median overall survival of only 13.3 months with treatment. Newly approved immune checkpoint inhi…
Admire Dube · STELLENBOSCH UNIVERSITY · 2024 · $303,416 — SUMMARY Tuberculosis remains a major global public health threat. Although relatively effective drug regimens are available, treatment failure remains a major roadblock to tuberculosis control. This is in part due to a high incidence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, as wel…
Jian-Xing Jay Ma · VIRGINIA COMMONWEALTH UNIVERSITY · 2024 · $538,028 — PROJECT SUMMARY Diabetic retinopathy (DR) is the most common cause of severe vision loss in the working-age population in the world. However, clinical studies have shown that approximately 40% DR patients do not adequately respond to anti-VEGF drugs. There is no drug treatment for those 40% DR pati…
Amaia Lujambio · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $589,164 — Chronic liver disease and its common sequela cirrhosis, are growing public health concerns, and major risk factors for the development of hepatocellular cancer (HCC). HCC incidence and mortality is growing in the USA. Optimal medical therapies for HCC are lacking. FDA approved agents are modestly ef…
Ju-Tao Guo · BARUCH S. BLUMBERG INSTITUTE · 2024 · $240,000 — Abstract This R21/R33 application is to develop our proprietary chemically ligated guide RNA (lgRNA)-based CRISPR/Cas9 gene editing technology for therapeutic elimination of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and cure of chronic hepatitis B (CHB). Prior studies have alre…
Gregory A. Newby · JOHNS HOPKINS UNIVERSITY · 2024 · $249,000 — PROJECT SUMMARY Genetic diseases impact over 1 in 50 newborns worldwide and yet there are no approved therapies capable of correcting the underlying genetic defects. As a result, most patients continue to suffer throughout their life and require frequent interventions to ameliorate symptoms. I aim …